Hermetica Superfood Encyclopedia
The Short Answer
Canthaxanthin from Chlorococcum sp. is a ketocarotenoid pigment that functions as a potent radical-scavenging antioxidant, quenching singlet oxygen and neutralizing reactive oxygen species through its conjugated polyene chromophore. Under optimized salinity stress (10 g/L NaCl), Chlorococcum sp. accumulates up to 294.55 ± 66.35 µg canthaxanthin per gram dry weight—a 2.7-fold increase over unstressed controls—while co-produced lipid fractions demonstrate anti-platelet-activating factor (anti-PAF) and antithrombin activity in human platelet assays with IC50 values of approximately 25–200 µg lipid.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordcanthaxanthin Chlorococcum microalgae
Canthaxanthin (Chlorococcum-derived) — botanical close-up
Health Benefits
**Antioxidant Protection**
Canthaxanthin's extended conjugated double-bond system enables efficient singlet oxygen quenching and free radical scavenging, potentially reducing oxidative damage to lipids, proteins, and DNA in biological systems.
**Anti-Platelet Aggregation Activity**: Lipid fractions from Chlorococcum sp
(enriched in SQDG, cerebrosides, PC, and PE) inhibit human platelet aggregation against both PAF and thrombin stimuli, with IC50 values of approximately 25–200 µg in in vitro assays, suggesting cardiovascular-protective potential.
**Antithrombotic Potential**
The antithrombin activity of Chlorococcum bioactive lipids, statistically comparable to lipid fractions from salmon and herring, points to a possible role in modulating clotting cascade activity, though this has not been confirmed in vivo.
**Photoprotective Pigmentation**
As a ketocarotenoid, canthaxanthin accumulates in tissues and can act as an endogenous photoprotectant, potentially reducing UV-induced oxidative stress in skin and retinal cells, consistent with its known behavior in other biological systems.
**Support for Carotenoid Diversity**: Chlorococcum sp
simultaneously produces astaxanthin, adonixanthin, β-carotene, and lutein alongside canthaxanthin, offering a multi-carotenoid profile that may exert synergistic antioxidant effects across different subcellular compartments.
**Lipid Bioactive Profile**
The co-production of sulfoquinovosyl diacylglycerols (SQDG) and cerebrosides (e.g., HexCer-t36:2) alongside canthaxanthin suggests a broader bioactive lipid matrix with potential immunomodulatory and membrane-stabilizing activities, though mechanistic studies remain preliminary.
Origin & History
Natural habitat
Chlorococcum is a genus of unicellular green microalgae found in marine and freshwater environments worldwide, including coastal and brackish waters. Under stress conditions such as elevated salinity (e.g., 10 g/L NaCl), nitrogen deprivation, or high light intensity, the alga dramatically upregulates ketocarotenoid biosynthesis, accumulating canthaxanthin and related pigments as photoprotective and osmoprotective metabolites. Commercial and research cultivation typically occurs in controlled photobioreactors or open raceway ponds, with stress induction used to maximize canthaxanthin yields.
“Chlorococcum microalgae have no documented history of use in traditional medicine systems; they were not identified or distinguished as a distinct genus until the era of modern microbiological taxonomy, and no ethnobotanical or ethnopharmacological records reference their deliberate therapeutic use. The pigment canthaxanthin itself has a broader modern history as a synthetic food colorant and aquaculture feed additive (used to impart pink coloration in farmed salmon and trout flesh since the 1980s), but this use is entirely distinct from Chlorococcum-derived material. Research interest in Chlorococcum sp. as a canthaxanthin source is an entirely contemporary phenomenon, driven by growing demand for natural, microalgae-based carotenoids as alternatives to synthetic canthaxanthin in food and nutraceutical applications. There are no notable historical texts, pharmacopeial monographs, or traditional preparation methods associated with this organism.”Traditional Medicine
Scientific Research
The available evidence for canthaxanthin from Chlorococcum sp. is limited to in vitro and cultivation-optimization studies, with no published clinical trials identified as of the current research horizon. Production studies document a 2.7-fold stress-induced increase in canthaxanthin yield (to 294.55 ± 66.35 µg/g dry weight under 10 g/L NaCl), validating the salinity-stress cultivation model, but these are bioprocess rather than bioactivity findings. Bioactivity data is restricted to platelet assays using human blood in vitro, where Chlorococcum lipid fractions inhibit PAF- and thrombin-induced aggregation at IC50 values of approximately 25–200 µg lipid, with results described as statistically significant compared to other marine lipid sources; however, no dose-response modeling, animal studies, or human pharmacokinetic data are available. The overall evidentiary base is early-stage and preclinical, with research priorities centered on strain optimization and lipid characterization rather than therapeutic application.
Preparation & Dosage
Traditional preparation
**Laboratory/Research Extract**
10 g/L NaCl), harvested, dried, and ground with sea sand; pigments are extracted with methanol/water solvent systems and separated via thin-layer chromatography (TLC), with quantification by spectrophotometry at 466 nm using a validated standard curve
Cells are cultivated under salt stress (.
**Biomass Form**
80 mg canthaxanthin per liter of culture
No commercial Chlorococcum canthaxanthin supplement is currently standardized; whole dried biomass from related microalgae is sometimes used in research at concentrations yielding up to 0..
**No Established Human Dose**
No clinical dosing regimen has been established for Chlorococcum-derived canthaxanthin; general carotenoid supplement literature is not directly applicable without species-specific bioavailability data.
**Lipid Fraction Preparations**
Bioactive lipid fractions used in platelet assays were prepared via solvent extraction and assessed at 25–200 µg lipid per assay well; these quantities are not translatable to oral dosing without pharmacokinetic bridging studies.
**Timing and Standardization**
No standardization percentage, bioavailability enhancer (e.g., oil-based vehicle), or dosing timing recommendation exists for this source specifically.
Nutritional Profile
Chlorococcum sp. biomass contains canthaxanthin as the dominant carotenoid at up to 294.55 ± 66.35 µg/g dry weight under optimized stress, with total carotenoids reaching approximately 716.92 ± 43.25 µg/g dry weight in standard culture conditions. Co-occurring carotenoids include astaxanthin, adonixanthin, β-carotene, and lutein, contributing to a diverse xanthophyll and carotene profile. The lipid fraction is notable for the presence of the glycolipid sulfoquinovosyl diacylglycerol (SQDG), the sphingolipid cerebroside HexCer-t36:2, phosphatidylcholine (PC), and phosphatidylethanolamine (PE), reflecting a complex polar lipid composition typical of photosynthetic microalgae. Macronutrient composition (protein, carbohydrate, and total lipid content) and micronutrient concentrations have not been reported in detail for the specific strains studied; bioavailability of microalgal canthaxanthin is expected to be influenced by cell wall integrity, lipid matrix composition, and co-ingestion of dietary fat, but no species-specific bioavailability data exists.
How It Works
Mechanism of Action
Canthaxanthin exerts its primary antioxidant activity through physical and chemical quenching of singlet oxygen (¹O₂) and scavenging of peroxyl radicals, facilitated by its nine conjugated carbon-carbon double bonds that efficiently dissipate excess excitation energy as heat. At the molecular level, this ketocarotenoid intercalates into lipid bilayers, protecting membrane phospholipids from peroxidative chain reactions, an effect linked to the presence of keto groups at the 4 and 4' positions of the β-ionone rings that enhance its electron-accepting capacity relative to non-keto carotenoids. Co-produced bioactive lipids from Chlorococcum sp.—particularly SQDG and glycosphingolipids (cerebrosides)—appear to modulate platelet activation by interfering with PAF receptor signaling and inhibiting thrombin-mediated platelet shape change and aggregation, though the precise receptor-binding or enzyme-inhibitory pathways have not been characterized at the molecular level for this specific algal source. Species-specific intracellular signaling pathways relevant to canthaxanthin from Chlorococcum remain uncharacterized, and extrapolation from other carotenoid sources should be made cautiously.
Clinical Evidence
No clinical trials have been conducted on canthaxanthin derived specifically from Chlorococcum sp. or on whole Chlorococcum extracts in human subjects. The most clinically suggestive data comes from in vitro platelet aggregation studies, where Chlorococcum lipid fractions (not isolated canthaxanthin alone) inhibit PAF- and thrombin-induced aggregation in human platelet-rich plasma, with IC50 values ranging from approximately 25 to 200 µg depending on the inducer and fraction tested. Effect sizes from these assays are described as comparable to marine lipids from salmon and herring, which have stronger supporting literature, but the absence of animal pharmacology, toxicology studies, and any human trial data means clinical confidence in therapeutic efficacy is very low. Researchers and clinicians should treat all bioactivity claims for this specific source as hypothesis-generating rather than evidence-based.
Safety & Interactions
No formal safety evaluation, toxicological study, or adverse event reporting exists for Chlorococcum-derived canthaxanthin in humans or animals, and the absence of data should not be interpreted as evidence of safety. Bioactive lipid fractions showed no apparent cytotoxicity in human platelet assays at concentrations up to 200 µg per assay, but this is an extremely limited safety signal and is not equivalent to a no-observed-adverse-effect level (NOAEL) for systemic exposure. Given the documented antithrombin and anti-PAF activity of co-produced lipid fractions, potential pharmacodynamic interactions with anticoagulants (e.g., warfarin, heparin, direct oral anticoagulants), antiplatelet agents (e.g., aspirin, clopidogrel), and thrombolytic drugs represent a theoretical but unquantified concern. Guidance for use during pregnancy, lactation, or in pediatric, geriatric, or immunocompromised populations cannot be provided due to the complete absence of relevant safety data; use outside controlled research settings is not currently supported by evidence.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Chlorococcum sp.green microalgae canthaxanthinmicroalgal ketocarotenoidβ,β-carotene-4,4'-dione (algal source)Chlorococcum canthaxanthin extract
Frequently Asked Questions
What is canthaxanthin from Chlorococcum and how does it differ from synthetic canthaxanthin?
Canthaxanthin from Chlorococcum sp. is a naturally biosynthesized ketocarotenoid pigment produced by this marine green microalga, particularly under salinity stress conditions, whereas synthetic canthaxanthin is chemically manufactured for use as a food colorant and aquaculture feed additive. The molecular structure (β,β-carotene-4,4'-dione) is identical, but the algal form is embedded within a complex biological matrix including co-produced lipids such as SQDG and cerebrosides, which may influence bioavailability and bioactivity in ways not studied for the isolated compound.
How much canthaxanthin does Chlorococcum produce, and can this yield be increased?
Under standard culture conditions (TAP medium), Chlorococcum sp. produces approximately 105.91 ± 12.81 µg canthaxanthin per gram of dry biomass, with total carotenoids reaching around 716.92 µg/g. Applying salt stress at 10 g/L NaCl increases canthaxanthin content to 294.55 ± 66.35 µg/g dry weight—a 2.7-fold increase—yielding up to 0.80 mg canthaxanthin per liter of culture, demonstrating that stress-induced cultivation is an effective strategy for boosting pigment output.
Is there any clinical evidence that Chlorococcum canthaxanthin is effective in humans?
No clinical trials have been conducted on canthaxanthin from Chlorococcum sp. in human subjects; all available efficacy data is limited to in vitro laboratory studies. The most notable bioactivity data involves lipid fractions (not canthaxanthin alone) from this alga inhibiting human platelet aggregation in platelet-rich plasma assays, with IC50 values of approximately 25–200 µg, but these findings require extensive additional research—including animal studies and human pharmacokinetic trials—before any clinical conclusions can be drawn.
Are there any safety concerns or drug interactions with Chlorococcum-derived canthaxanthin?
No formal human safety studies exist for Chlorococcum-derived canthaxanthin, and its toxicological profile is undefined. A theoretical concern arises from the antithrombin and anti-PAF activities of co-produced lipid fractions, which suggest possible additive or potentiating interactions with anticoagulant medications (e.g., warfarin, heparin), antiplatelet drugs (e.g., aspirin, clopidogrel), and thrombolytics; individuals on these medications should avoid uncharacterized algal extracts until safety data is available.
What is the recommended dose of canthaxanthin from Chlorococcum for health benefits?
No established or recommended supplemental dose for Chlorococcum-derived canthaxanthin exists, as no clinical trials or pharmacokinetic studies have been completed for this specific source. The in vitro platelet assay data used lipid fractions at 25–200 µg per well, which cannot be meaningfully translated to human oral doses without absorption, distribution, metabolism, and excretion (ADME) data; until such research is conducted, no safe or effective dose range can be stated.
Does canthaxanthin from Chlorococcum absorb better with dietary fat compared to other carotenoid sources?
Canthaxanthin is a fat-soluble xanthophyll carotenoid that requires dietary lipids for optimal absorption in the small intestine, similar to other carotenoids. Chlorococcum-derived canthaxanthin is naturally embedded within the microalgal lipid matrix, which may enhance bioavailability compared to isolated synthetic forms, though direct comparative absorption studies in humans remain limited. Consuming canthaxanthin supplements with a meal containing dietary fat significantly improves intestinal uptake and systemic distribution.
Which populations would benefit most from canthaxanthin supplementation from Chlorococcum?
Individuals with elevated oxidative stress, including athletes, smokers, and those with age-related vision concerns, may derive the most benefit from canthaxanthin's potent antioxidant and singlet oxygen-quenching properties. People at cardiovascular risk who could benefit from anti-platelet aggregation support—such as those with thrombosis concerns or impaired blood flow—represent another target population, given Chlorococcum's phospholipid-rich lipid fractions. Vegans and vegetarians seeking natural carotenoid sources may also prefer microalgal canthaxanthin over animal-derived alternatives.
How does the phospholipid composition of Chlorococcum canthaxanthin affect its biological activity compared to purified canthaxanthin alone?
Chlorococcum sp. naturally contains a unique lipid profile including SQDG (sulfoquinovosyl diacylglycerol), cerebrosides, phosphatidylcholine (PC), and phosphatidylethanolamine (PE), which work synergistically with canthaxanthin to modulate platelet aggregation and enhance cellular antioxidant effects. These co-extracted phospholipids improve canthaxanthin's integration into cell membranes and may potentiate its protective effects against lipid peroxidation in ways that purified canthaxanthin alone cannot achieve. The whole-microalgal extract thus offers advantages in bioactivity that reflect the principle of natural synergy between the active carotenoid and its native lipid environment.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w canthaxanthin-from-chlorococcum-chlorococcum-sp-marine-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
